clinicaltrialsarena1d
AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials
AbbVie has revealed positive data from a post-hoc analysis of Phase III trials of RINVOQ in treating atopic dermatitis (AD).
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
Pharmabiz4d
EMA committee recommends marketing approval for AbbVie’s mirvetuximab soravtansine for the treatment of certain adult ovarian cancer
North Chicago, Illinois Monday, September 23, 2024, 13:00 Hrs [IST] ...
BioWorld4d
EMA’s CHMP recommends Hympavzi for hemophilia, Elahere for cancer
For once, the EMA appears to have pipped the U.S. FDA to the post, with Pfizer Inc.’s hemophilia A and B therapy Hympavzi (marstacimab) recommended for approval in Europe on Sept. 20, while the U.S.
Medscape6d
EMA Backs Approval of Elahere for Ovarian Cancer
Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...
AbbVie: CHMP Adopts Positive Opinion For Mirvetuximab Soravtansine - Quick Facts
AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...
Abbvie Slides on ELAHERE Opinion of its Cancer Treatment
AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...